title: Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
abstract: OBJECTIVE
  We compared the efficacy and safety of the combined therapy of daily interferon alpha-2b and ribavirin with those of interferon alpha-2b three times per week alone or in combination with ribavirin in non-responder patients with hepatitis C virus (HCV) infection.
  
  
  METHODS
  A total of 376 patients were randomly assigned to receive interferon alpha-2b (6 MU three times per week for 24 weeks followed by 3 MU three times per week for 24 weeks) alone (group A) or in combination with ribavirin for 48 weeks (group B), or daily interferon alpha-2b (3 MU per day for 24 weeks followed by 3 MU three times per week for 24 weeks) and ribavirin (group C).
  
  
  RESULTS
  After 24 weeks of therapy, HCV RNA was undetectable in 11.7, 24.0, and 37.8% for groups A, B, and C, respectively. Sustained virological response was more frequent in patients who received combination therapy with three times weekly interferon (20.9%) or daily interferon (26.0%) than in patients who received interferon alone (5.8%) (P<0.001). The predictive HCV parameters for sustained response were a low viral load on day 7 and a negative HCV RNA on week 12.
  
  
  CONCLUSIONS
  In conclusion, in non-responder patients with chronic hepatitis C, virological response with daily interferon and ribavirin, compared to interferon monotherapy, was significantly improved during treatment, although sustained virological response was similar for both combination therapies with ribavirin and three times a week or daily interferon.
authors.affiliation: Service d'Hépato-Gastroentérologie, Centre Hospitalier Universitaire, Hôpital du Haut-Lévêque, 33604 Pessac Cedex, France.
authors.forename: Victor
authors.initials: V
authors.lastname: de Lédinghen
authors.forename: Pascale
authors.initials: P
authors.lastname: Trimoulet
authors.forename: Maria
authors.initials: M
authors.lastname: Winnock
authors.forename: Pierre-Henri
authors.initials: PH
authors.lastname: Bernard
authors.forename: Marc
authors.initials: M
authors.lastname: Bourlière
authors.forename: Isabelle
authors.initials: I
authors.lastname: Portal
authors.forename: André-Jean
authors.initials: AJ
authors.lastname: Rémy
authors.forename: Nathalie
authors.initials: N
authors.lastname: Szostak
authors.forename: Stéphane
authors.initials: S
authors.lastname: Lévy
authors.forename: Albert
authors.initials: A
authors.lastname: Tran
authors.forename: Armand
authors.initials: A
authors.lastname: Abergel
authors.forename: Geneviève
authors.initials: G
authors.lastname: Chêne
authors.forename: Hervé
authors.initials: H
authors.lastname: Fleury
authors.forename: Patrice
authors.initials: P
authors.lastname: Couzigou
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008103:Liver Cirrhosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin